100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Summary Cell Growth and Differentiation - translational (MM1TR) $6.86
Add to cart

Summary

Summary Cell Growth and Differentiation - translational (MM1TR)

 7 views  0 purchase
  • Course
  • Institution

Comprehensive up-to-date summary of the first-year MMD course Cell Growth and Differnetiation - Translational (MM1TR). Save yourself a huge amount of time studying for this exam by using this summary!

Preview 3 out of 20  pages

  • October 24, 2023
  • 20
  • 2022/2023
  • Summary
avatar-seller
Summary cell growth & differentiation
– Translational: developmental
disorders and malignancies




1

,Chapter 1 Blood cell disorders
Hematopoiesis is the development of blood cells  takes place in the bone marrow
 Hematopoietic stem cells (HSCs) are present in the bone marrow give rise to all blood cells  differentiate in
the BM into progenitor cells
 Differentiation is steered by growth factors  extrinsic
 In combination with transcription factors  stem cell intrinsic
o Intrinsic factors might change over time  might be the reason why children in average
develop lymphoid leukaemia more often than myeloid leukaemia than elderly
 Progenitor cells  referred to as ‘blasts’ remain within the BM and only enter the periphery when
fully differentiated
o Lymphoid
o Myeloid
 HSCs have the capacity to self-renew  very slow division so more Quiescent
 Multi-hit model: mutations passed on to daughter cells
 With each SC division the number of mutations increases
 Commonly used marker for blasts and HSCs is CD34
 Differentiation is tightly regulated  mutations can cause disbalance
 Many genes involved
 Driver mutations: almost all of these are in signalling regulation




Leukaemia vs myelodysplastic syndrome
A quite severe and common developmental disorder in hematopoiesis is leukemia:
 Leukemia is the accumulation of immature cells in the BM  blasts do not leave the BM
 Upregulated proliferation  growth factor independent
 Decreased apoptosis
 And a block in differentiation  leads to accumulation of blasts
 Acute when >20% of cells in the BM are blasts

Myelodysplastic syndrome: we speak of myelodysplastic syndrome when the blood cells have an abnormal shape
but they do differentiate
 Indolent MDS: So unlike in leukaemia cells differentiate
 Aggressive MDS: And with aggressive MDS the cells look dysplastic on top of their blocked differentiation
 Thus can develop into leukaemia at a later stage  we speak of this when differentiation gets
blocked and blasts start accumulating
 Affected lineage differs per patient  hence symptoms differ per patient

Both leukaemia (AML) and myelodysplastic syndrome (MDS) have a higher incidence amongst the elderly which
largely impacts treatment and prognosis.

2

, Development of leukaemia
Mutations are acquired due to carcinogenic agents, and naturally during cell division  all mutations in HSCs are
passed on to daughter cells
 Development of leukaemia is a multi-hit process  multiple driver mutations required to acquire the cancer
hallmarks
 These mutations are in genes that regulate the balance between proliferation and apoptosis  give
the cell a growth advantage
o Positive selection leads to mutation co-occurrence
 Causes clonal expansion
 CHIPs might increase the risk for leukaemia because they can be malignant in combination with
other mutations
 Full blown leukaemia is a combination of mutations in 2-3 genes from different categories:
 I: growth factor receptors
 II: signal transduction molecules
 III: gene expression regulation
o TFs
o Epigenetic regulators
o RNA splicing factors
o Chromatin organisation
 IV: apoptosis

Enzymes involved in DNA (de)methylation are often mutated in AML  hypermethylation of promoters for tumour-
suppressor genes or demethylation of proto-oncogenes
 DNMT(3a): copy methylation profile after division  hyperactivity
 Hypomethylating agents: Azacitidine and decitabine are cytosine analogues  incorporated at C-
sites but cannot be methylated
 TET(2) proteins: operate in active demethylation  need α-ketogluterate as a substrate

 IDH1/2: convert α-KG into α-HG
 Inhibitors of IDH1/2 increase α-KG levels




3

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller lisaverhoeven80. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $6.86. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

50064 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$6.86
  • (0)
Add to cart
Added